Robert S Hogg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5975607/publications.pdf

Version: 2024-02-01

383 papers 23,560 citations

9264 74 h-index 138 g-index

394 all docs

394 docs citations

times ranked

394

15814 citing authors

#	Article	IF	Citations
1	Supportive housing building policies and resident psychological needs: a qualitative analysis using self-determination theory. Housing Studies, 2023, 38, 642-660.	2.4	1
2	Neighbourhood-level material deprivation and response to combination antiretroviral therapy in the Canadian Observational Cohort (CANOC): a longitudinal cohort study. CMAJ Open, 2022, 10, E183-E189.	2.4	0
3	Impact of Canadian human immunodeficiency virus non-disclosure case law on experiences of violence from sexual partners among women living with human immunodeficiency virus in Canada: Implications for sexual rights. Women's Health, 2022, 18, 174550652210759.	1.5	2
4	Using Google Trends to Inform the Population Size Estimation and Spatial Distribution of Gay, Bisexual, and Other Men Who Have Sex With Men: Proof-of-concept Study. JMIR Public Health and Surveillance, 2021, 7, e27385.	2.6	2
5	Overdose mortality is reducing the gains in life expectancy of antiretroviral-treated people living with HIV in British Columbia, Canada. International Journal of Drug Policy, 2021, 96, 103195.	3.3	4
6	Predictors of COVID-19 testing rates: A cross-country comparison. International Journal of Infectious Diseases, 2021, 104, 370-372.	3.3	17
7	Assessing Bear/Cub/Otter identity and history of cardiovascular disease among gay, bisexual, and other men who have sex with men in Metro Vancouver. Canadian Journal of Human Sexuality, 2021, 30, 78-93.	1.6	1
8	The opioid crisis is driving mortality among under-served people living with HIV in British Columbia, Canada. BMC Public Health, 2021, 21, 680.	2.9	5
9	Incidence of diabetes mellitus among people living with and without HIV in British Columbia, Canada between 2001 and 2013: a longitudinal population-based cohort study. BMJ Open, 2021, 11, e048744.	1.9	3
10	Longitudinal Analysis of HIV Risk and Substance Use Patterns for Men Who Have Sex With Men and Women and Men Who Have Sex With Men Only. Journal of Bisexuality, 2021, 21, 405-423.	1.3	0
11	Awareness and Understanding of HIV Non-disclosure Case Law and the Role of Healthcare Providers in Discussions About the Criminalization of HIV Non-disclosure Among Women Living with HIV in Canada. AIDS and Behavior, 2020, 24, 95-113.	2.7	13
12	Assessing the impact of food insecurity on HIV medication adherence in the context of an integrated care programme for people living with HIV in Vancouver, Canada. Public Health Nutrition, 2020, 23, 683-690.	2.2	11
13	Understanding the pervasiveness of trauma within a housing facility for people living with HIV. Housing Studies, 2020, 35, 1073-1087.	2.4	4
14	Crystal Methamphetamine Use and Initiation among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV in a Treatment as Prevention Environment. Substance Use and Misuse, 2020, 55, 2428-2437.	1.4	11
15	Overdose Risk and Acquiring Opioids for Nonmedical Use Exclusively from Physicians in Vancouver, Canada. Substance Use and Misuse, 2020, 55, 1912-1918.	1.4	3
16	Quality of life of older women living with HIV: comparative assessment of physical and mental health-related markers using a large Canadian Sexual and Reproductive Health Cohort Study. HIV Research and Clinical Practice, 2019, 20, 35-47.	1.1	8
17	HIV, schizophrenia, and all-cause mortality: A population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. Schizophrenia Research, 2019, 209, 198-205.	2.0	9
18	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal of Epidemiology, 2019, 188, 2097-2109.	3.4	32

#	Article	IF	Citations
19	A gender-based analysis of nonmedical prescription opioid use among people who use illicit drugs. Addictive Behaviors, 2019, 97, 42-48.	3.0	2
20	Substance Use as a Mechanism for Social Inclusion among Gay, Bisexual, and Other Men Who Have Sex with Men in Vancouver, Canada. Substance Use and Misuse, 2019, 54, 1945-1955.	1.4	17
21	"Condoms are … like public transit. It's something you want everyone else to take― Perceptions and use of condoms among HIV negative gay men in Vancouver, Canada in the era of biomedical and seroadaptive prevention. BMC Public Health, 2019, 19, 120.	2.9	12
22	Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis. BMJ Open, 2019, 9, e025874.	1.9	43
23	Agreement between gay, bisexual and other men who have sex with men's period prevalence and event-level recall of sexual behaviour: an observational respondent-driven sampling study. Sexual Health, 2019, 16, 84.	0.9	8
24	Factors associated with delayed and late ART initiation among people living with HIV in BC: results from the engage study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 885-892.	1.2	9
25	Lower Optimal Treatment Adherence Among Youth Living With HIV in a Universal Health Care Setting Where ART Is Available at No Cost. Journal of Adolescent Health, 2019, 64, 509-515.	2.5	5
26	Sexual Self-Efficacy and Gender: A Review of Condom Use and Sexual Negotiation Among Young Men and Women in Sub-Saharan Africa. Journal of Sex Research, 2018, 55, 522-539.	2.5	50
27	HIV treatment optimism and crystal methamphetamine use and initiation among HIV-negative men who have sex with men in Vancouver, Canada: A longitudinal analysis. Drug and Alcohol Dependence, 2018, 185, 67-74.	3.2	8
28	Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. BMJ Open, 2018, 8, e019115.	1.9	17
29	A latent class analysis of substance use and culture among gay, bisexual and other men who have sex with men. Culture, Health and Sexuality, 2018, 20, 1424-1439.	1.8	37
30	The additive effects of depressive symptoms and polysubstance use on HIV risk among gay, bisexual, and other men who have sex with men. Addictive Behaviors, 2018, 82, 158-165.	3.0	23
31	Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. AIDS and Behavior, 2018, 22, 1530-1540.	2.7	6
32	Seroadaptive Strategies of Vancouver Gay and Bisexual Men in a Treatment as Prevention Environment. Journal of Homosexuality, 2018, 65, 524-539.	2.0	13
33	Gender, Sexual Self-Efficacy and Consistent Condom Use Among Adolescents Living in the HIV Hyper-Endemic Setting of Soweto, South Africa. AIDS and Behavior, 2018, 22, 671-680.	2.7	32
34	Prevalence and predictors of food insecurity among people living with HIV affiliated with AIDS service organizations in Ontario, Canada. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 663-671.	1,2	18
35	Gender differences in prevalence and correlates of high sexual self-efficacy among adolescents in Soweto, South Africa: implications for gender-sensitive research and programming. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 435-443.	1.2	5
36	Factors associated with low neighborhood cohesion among women living with HIV impacted by social-structural inequities in British Columbia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 318-324.	1.2	3

#	Article	IF	CITATIONS
37	Estimating the Size of the MSM Population in Metro Vancouver, Canada, Using Multiple Methods and Diverse Data Sources. Journal of Urban Health, 2018, 95, 188-195.	3.6	25
38	Attrition Across the HIV Cascade of Care Among a Diverse Cohort of Women Living With HIV in Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 226-236.	2.1	39
39	Sexual Orientation Measurement, Bisexuality, and Mental Health in a Sample of Men Who Have Sex with Men in Vancouver, Canada. Journal of Bisexuality, 2018, 18, 299-317.	1.3	3
40	Understanding the HIV care continuum. Lancet HIV,the, 2018, 5, e269-e270.	4.7	38
41	Predictors of Facebook User Engagement With Health-Related Content for Gay, Bisexual, and Other Men Who Have Sex With Men: Content Analysis. JMIR Public Health and Surveillance, 2018, 4, e38.	2.6	25
42	Using Geosocial Networking Apps to Understand the Spatial Distribution of Gay and Bisexual Men: Pilot Study. JMIR Public Health and Surveillance, 2018, 4, e61.	2.6	4
43	Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. BMC Infectious Diseases, 2017, 17, 174.	2.9	87
44	Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. Lancet HIV,the, 2017, 4, e270-e276.	4.7	51
45	Exploring the role of sex-seeking apps and websites in the social and sexual lives of gay, bisexual and other men who have sex with men: a cross-sectional study. Sexual Health, 2017, 14, 229.	0.9	26
46	Changes in smoking status among a longitudinal cohort of gay, bisexual, and other men who have sex with men in Vancouver, Canada. Drug and Alcohol Dependence, 2017, 179, 370-378.	3.2	11
47	Awareness and understanding of HIV non-disclosure case law among people living with HIV who use illicit drugs in a Canadian setting. International Journal of Drug Policy, 2017, 43, 113-121.	3.3	5
48	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral na \tilde{A} ve patients. BMC Infectious Diseases, 2017, 17, 266.	2.9	7
49	Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development. BMC Cancer, 2017, 17, 270.	2.6	31
50	Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study. BMC Research Notes, 2017, 10, 138.	1.4	27
51	Harder-to-reach people living with HIV experiencing high prevalence of all-type mental health disorder diagnosis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 696-704.	1.2	9
52	Progress towards the United Nations 90â€90â€90 and 95â€95â€95 targets: the experience in British Columbia, Canada. Journal of the International AIDS Society, 2017, 20, e25011.	3.0	28
53	Conspiracy beliefs and knowledge about HIV origins among adolescents in Soweto, South Africa. PLoS ONE, 2017, 12, e0165087.	2.5	23
54	Cohort profile: The Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS). PLoS ONE, 2017, 12, e0184708.	2.5	62

#	Article	IF	CITATIONS
55	A latent class analysis of sexual and romantic relationships among HIV-positive and HIV-negative gay and bisexual men in Vancouver. Canadian Journal of Human Sexuality, 2017, 26, 78-96.	1.6	2
56	The Botsha Bophelo Adolescent Health Study: A profile of adolescents in Soweto, South Africa. Southern African Journal of HIV Medicine, 2017, 18, 731.	0.9	25
57	A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NAâ€ACCORD and CCASAnet clinical cohorts. Journal of the International AIDS Society, 2016, 19, 20707.	3.0	8
58	Establishing the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study. BMC Medical Research Methodology, 2016, 16, 101.	3.1	50
59	The population impact of eliminating homelessness on HIV viral suppression among people who use drugs. Aids, 2016, 30, 933-942.	2.2	19
60	Prevalence and predictors of facing a legal obligation to disclose HIV serostatus to sexual partners among people living with HIV who inject drugs in a Canadian setting:a cross-sectional analysis. CMAJ Open, 2016, 4, E169-E176.	2.4	8
61	The effect of socioeconomic disadvantage on strategies to end the AIDS epidemic. Lancet Public Health, The, 2016, 1, e6-e7.	10.0	1
62	"My job is to deal with what I can†HIV care providers' perspectives on adherence to HAART, addictions, and comprehensive care delivery in Vancouver, British Columbia. Critical Public Health, 2016, 26, 542-553.	2.4	2
63	No association between HIV status and risk of non-fatal overdose among people who inject drugs in Vancouver, Canada. Addictive Behaviors, 2016, 60, 8-12.	3.0	8
64	Pre-exposure Prophylaxis Awareness Among Gay and Other Men who have Sex with Men in Vancouver, British Columbia, Canada. AIDS and Behavior, 2016, 20, 1408-1422.	2.7	35
65	Factors Associated with Productive Recruiting in a Respondent-Driven Sample of Men who Have Sex with Men in Vancouver, Canada. Journal of Urban Health, 2016, 93, 379-387.	3.6	18
66	Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study. Lancet HIV,the, 2016, 3, e231-e238.	4.7	168
67	High prevalence of depression symptomology among adolescents in Soweto, South Africa associated with being female and cofactors relating to HIV transmission. Vulnerable Children and Youth Studies, 2016, 11, 263-273.	1.1	19
68	Heightened epidemic in men who have sex with men in Brazil. Lancet HIV, the, 2016, 3, e454-e455.	4.7	0
69	Effects of a switch from tenofovirâ€to abacavirâ€based antiretroviral therapy, with or without atazanavir, on renal function. Journal of the International AIDS Society, 2016, 19, 20995.	3.0	3
70	Does size really matter? A sensitivity analysis of number of seeds in a respondent-driven sampling study of gay, bisexual and other men who have sex with men in Vancouver, Canada. BMC Medical Research Methodology, 2016, 16, 157.	3.1	17
71	Prevalence, type, and correlates of trauma exposure among adolescent men and women in Soweto, South Africa: implications for HIV prevention. BMC Public Health, 2016, 16, 1191.	2.9	27
72	HIV Community Viral Load and Factors Associated With Elevated Viremia Among a Community-Based Sample of Men Who Have Sex With Men in Vancouver, Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 87-95.	2.1	52

#	Article	IF	CITATIONS
73	Event-Level Analysis of Anal Sex Roles and Sex Drug Use Among Gay and Bisexual Men in Vancouver, British Columbia, Canada. Archives of Sexual Behavior, 2016, 45, 1443-1451.	1.9	23
74	Substance use, sexual behaviour and prevention strategies of Vancouver gay and bisexual men who recently attended group sex events. Culture, Health and Sexuality, 2016, 18, 361-376.	1.8	23
75	HIV testing behaviour and use of risk reduction strategies by HIV risk category among MSM in Vancouver. International Journal of STD and AIDS, 2016, 27, 281-287.	1.1	18
76	Association between Food Insecurity and Procurement Methods among People Living with HIV in a High Resource Setting. PLoS ONE, 2016, 11, e0157630.	2.5	26
77	Including Online-Recruited Seeds: A Respondent-Driven Sample of Men Who Have Sex With Men. Journal of Medical Internet Research, 2016, 18, e51.	4.3	42
78	The impact of criminalization of HIV nonâ€disclosure on the healthcare engagement of women living with HIV in Canada: a comprehensive review of the evidence. Journal of the International AIDS Society, 2015, 18, 20572.	3.0	34
79	Virologic suppression and mortality of patients who migrate for HIV care in the province of British Columbia, Canada, from 2003 to 2012: a retrospective cohort study. BMC Health Services Research, 2015, 15, 376.	2.2	2
80	Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study. BMC Infectious Diseases, 2015, 15, 453.	2.9	0
81	Suicide mortality among people accessing highly active antiretroviral therapy for HIV/AIDS in British Columbia: a retrospective analysis. CMAJ Open, 2015, 3, E140-E148.	2.4	30
82	Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. Aids, 2015, 29, 1871-1882.	2.2	34
83	The impact of scalingâ€up combination antiretroviral therapy on patterns of mortality among HIVâ€positive persons in British Columbia, Canada. Journal of the International AIDS Society, 2015, 18, 20261.	3.0	29
84	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. Journal of the International AIDS Society, 2015, 18, 20024.	3.0	22
85	Gay and bisexual men's awareness and knowledge of treatment as prevention: findings from the Momentum Health Study in Vancouver, Canada. Journal of the International AIDS Society, 2015, 18, 20039.	3.0	34
86	Sexual inactivity and sexual satisfaction among women living with HIV in Canada in the context of growing social, legal and public health surveillance. Journal of the International AIDS Society, 2015, 18, 20284.	3.0	39
87	Unlocking adherence: is gender the key?. Lancet HIV,the, 2015, 2, e2-e3.	4.7	2
88	Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study. Pharmacoeconomics, 2015, 33, 243-253.	3.3	19
89	High-Intensity Cannabis Use and Adherence to Antiretroviral Therapy Among People Who Use Illicit Drugs in a Canadian Setting. AIDS and Behavior, 2015, 19, 120-127.	2.7	40
90	Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. Lancet HIV,the, 2015, 2, e393-e400.	4.7	36

#	Article	IF	CITATIONS
91	The Impact of Clinical, Demographic and Risk Factors on Rates of HIV Transmission: A Population-based Phylogenetic Analysis in British Columbia, Canada. Journal of Infectious Diseases, 2015, 211, 926-935.	4.0	89
92	Vets, denialists and rememberers: social typologies of patient adherence and non-adherence to HAART from the perspective of HIV care providers. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 758-761.	1.2	7
93	AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV,the, 2015, 2, e92-e97.	4.7	54
94	Seroprevalence of hepatitis C and correlates of seropositivity among men who have sex with men in Vancouver, Canada: a cross-sectional survey: TableÂ1. Sexually Transmitted Infections, 2015, 91, 430-433.	1.9	17
95	HAART slows progression to anal cancer in HIV-infected MSM. Aids, 2015, 29, 305-311.	2.2	28
96	Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infectious Diseases, 2015, 15, 274.	2.9	103
97	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	5.8	142
98	Highâ€intensity cannabis use associated with lower plasma human immunodeficiency virusâ€1 <scp>RNA</scp> viral load among recently infected people who use injection drugs. Drug and Alcohol Review, 2015, 34, 135-140.	2.1	53
99	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort. International Journal of Epidemiology, 2015, 44, 58-67.	1.9	31
100	Gender Inequities in Quality of Care among HIV-Positive Individuals Initiating Antiretroviral Treatment in British Columbia, Canada (2000–2010). PLoS ONE, 2014, 9, e92334.	2.5	40
101	Association between Childhood Physical Abuse, Unprotected Receptive Anal Intercourse and HIV Infection among Young Men Who Have Sex with Men in Vancouver, Canada. PLoS ONE, 2014, 9, e100501.	2.5	18
102	High rates of lifetime and recent violence observed among harder-to-reach women living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 587-594.	1.2	17
103	The effect of history of injection drug use and alcoholism on HIV disease progression. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 123-129.	1.2	16
104	The impact of unstable housing on emergency department use in a cohort of HIV-positive people in a Canadian setting. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 53-64.	1.2	8
105	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 2014, 11, e1001718.	8.4	100
106	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. Clinical Infectious Diseases, 2014, 58, 1185-1189.	5.8	65
107	Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: an observational cohort study. Sexually Transmitted Infections, 2014, 90, 418-422.	1.9	22

Cohort Profile: Seek and Treat for the Optimal Prevention of HIV/AIDS in British Columbia (STOP) Tj ETQq0.00 rgBT/Overlock 10 Tf 50.60

#	Article	IF	CITATIONS
109	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. CMAJ Open, 2014, 2, E318-E329.	2.4	16
110	Digital surveillance for enhanced detection and response to outbreaks. Lancet Infectious Diseases, The, 2014, 14, 1035-1037.	9.1	46
111	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal of Epidemiology, 2014, 43, 691-702.	1.9	64
112	Process Monitoring of an HIV Treatment as Prevention Program in British Columbia, Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, e94-e109.	2.1	16
113	Temporal trends in the discontinuation of first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 2202-2209.	3.0	24
114	Impact of the Data Collection on Adverse Events of Anti-HIV Drugs Cohort Study on Abacavir Prescription among Treatment-Naive, HIV-Infected Patients in Canada. Journal of the International Association of Providers of AIDS Care, 2014, 13, 153-159.	1.5	6
115	Factors Associated with Late Initiation of Highly Active Antiretroviral Therapy among Young HIV-Positive Men and Women Aged 18 to 29 Years in Canada. Journal of the International Association of Providers of AIDS Care, 2014, 13, 56-62.	1.5	10
116	The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infectious Diseases, The, 2014, 14, 40-49.	9.1	178
117	Community mapping and respondent-driven sampling of gay and bisexual men's communities in Vancouver, Canada. Culture, Health and Sexuality, 2014, 16, 288-301.	1.8	27
118	Factors Associated with Disclosure of HIV Status Among a Cohort of Individuals on Antiretroviral Therapy in British Columbia, Canada. AIDS and Behavior, 2014, 18, 1014-1026.	2.7	17
119	Correlates of Unstructured Antiretroviral Treatment Interruption in a Cohort of HIV-Positive Individuals in British Columbia. AIDS and Behavior, 2014, 18, 2240-2248.	2.7	11
120	HIV treatment strategies that can weather future challenges. Lancet Infectious Diseases, The, 2014, 14, 534-535.	9.1	1
121	Adolescent-friendly technologies as potential adjuncts for health promotion. Health Education, 2014, 114, 304-318.	0.9	13
122	Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. Aids, 2014, 28, 121-127.	2.2	14
123	Trends in Plasma HIV-RNA Suppression and Antiretroviral Resistance in British Columbia, 1997–2010. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 107-114.	2.1	14
124	Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The "HIV Treatment as Prevention―Experience in a Canadian Setting. PLoS ONE, 2014, 9, e87872.	2.5	272
125	Risks for HIV and other sexually transmitted infections among Asian men who have sex with men in Vancouver, British Columbia: a cross-sectional survey. BMC Public Health, 2013, 13, 763.	2.9	4
126	Intergenerational Sex as a Risk Factor for HIV Among Young Men Who Have Sex with Men: A Scoping Review. Current HIV/AIDS Reports, 2013, 10, 398-407.	3.1	30

#	Article	IF	CITATIONS
127	Identifying self-perceived HIV-related stigma in a population accessing antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 95-102.	1.2	21
128	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. Journal of Infectious Diseases, 2013, 208, 1240-1249.	4.0	43
129	Cohort Profile: Longitudinal Investigations into Supportive and Ancillary health services. International Journal of Epidemiology, 2013, 42, 947-955.	1.9	13
130	Social–structural factors associated with supportive service use among a cohort of HIV-positive individuals on antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 937-947.	1.2	3
131	Retention Among North American HIV-Infected Persons in Clinical Care, 2000–2008. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 356-362.	2.1	131
132	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 149-163.	2.1	188
133	Invasive Cervical Cancer Risk Among HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 405-413.	2.1	184
134	HIV-1 Disease Progression During Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 653-659.	2.1	28
135	Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. Aids, 2013, 27, 2863-2872.	2.2	6
136	Relationship between Food Insecurity and Mortality among HIV-Positive Injection Drug Users Receiving Antiretroviral Therapy in British Columbia, Canada. PLoS ONE, 2013, 8, e61277.	2.5	70
137	Gender Differences in Clinical Outcomes among HIV-Positive Individuals on Antiretroviral Therapy in Canada: A Multisite Cohort Study. PLoS ONE, 2013, 8, e83649.	2.5	39
138	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE, 2013, 8, e81355.	2.5	1,111
139	Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada. PLoS ONE, 2013, 8, e54416.	2.5	46
140	Incidence and Predictors of Pregnancy among a Cohort of HIV-Positive Women Initiating Antiretroviral Therapy in Mbarara, Uganda. PLoS ONE, 2013, 8, e63411.	2.5	51
141	Evaluation of Treatment Tolerability, Satisfaction and Laboratory Parameters in HIV+ Patients Switching from Ritonavir Capsule to Tablet Formulation§. Current HIV Research, 2013, 11, 231-237.	0.5	2
142	Women's Health Care Utilization among Harder-to-Reach HIV-Infected Women ever on Antiretroviral Therapy in British Columbia. AIDS Research and Treatment, 2012, 2012, 1-8.	0.7	7
143	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	1.9	34
144	Cohort Profile: The TASO-CAN Cohort Collaboration. International Journal of Epidemiology, 2012, 41, 946-950.	1.9	7

9

#	Article	IF	Citations
145	Availability of nutritional support services in HIV care and treatment sites in sub-Saharan African countries. Public Health Nutrition, 2012, 15, 938-947.	2.2	31
146	Young Age Predicts Poor Antiretroviral Adherence and Viral Load Suppression Among Injection Drug Users. AIDS Patient Care and STDs, 2012, 26, 274-280.	2.5	47
147	Factors Predictive of 30-Day Postoperative Mortality in HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy. Annals of Surgery, 2012, 256, 170-176.	4.2	5
148	Social and Environmental Predictors of Plasma HIV RNA Rebound Among Injection Drug Users Treated With Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 393-399.	2.1	52
149	Factors Associated with Antiretroviral Medication Adherence among HIV-Positive Adults Accessing Highly Active Antiretroviral Therapy (HAART) in British Columbia, Canada. Journal of the International Association of Providers of AIDS Care, 2012, 11, 134-141.	1.2	34
150	Acceptability of human papillomavirus vaccination and sexual experience prior to disclosure to health care providers among men who have sex with men in Vancouver, Canada: Implications for targeted vaccination programs. Vaccine, 2012, 30, 5755-5760.	3.8	36
151	Deadly Public Policy: What the Future Could Hold for the HIV Epidemic among Injection Drug Users in Vancouver. Current HIV/AIDS Reports, 2012, 9, 394-400.	3.1	14
152	Validating a Shortened Depression Scale (10 Item CES-D) among HIV-Positive People in British Columbia, Canada. PLoS ONE, 2012, 7, e40793.	2.5	402
153	Conversations With Mothers: Exploring Reasons for Prevention of Mother-to-Child Transmission (PMTCT) Failures in the Era of Programmatic Scale-Up in Soweto, South Africa. AIDS and Behavior, 2012, 16, 91-98.	2.7	44
154	Disparities in the Burden of HIV/AIDS in Canada. PLoS ONE, 2012, 7, e47260.	2.5	36
155	Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. PLoS ONE, 2012, 7, e47859.	2.5	21
156	"The way I see it― the effect of stigma and depression on self-perceived body image among HIV-positive individuals on treatment in British Columbia, Canada. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 1456-1466.	1.2	17
157	Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clinical Epidemiology, 2011, 3, 21.	3.0	18
158	The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ: British Medical Journal, 2011, 343, d7031-d7031.	2.3	162
159	Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. Aids, 2011, 25, 701-705.	2.2	53
160	Childbearing Intentions of HIV-Positive Women of Reproductive Age in Soweto, South Africa: The Influence of Expanding Access to HAART in an HIV Hyperendemic Setting. American Journal of Public Health, 2011, 101, 350-358.	2.7	89
161	Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. European Journal of Gastroenterology and Hepatology, 2011, 23, 45-50.	1.6	8
162	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 253-260.	2.1	19

#	Article	IF	Citations
163	Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020. AIDS Research and Therapy, 2011, 8, 13.	1.7	15
164	HIV Incidence and Prevalence Among Aboriginal Peoples in Canada. AIDS and Behavior, 2011, 15, 214-227.	2.7	31
165	Sticking to It: The Effect of Maximally Assisted Therapy on Antiretroviral Treatment Adherence Among Individuals Living with HIV Who are Unstably Housed. AIDS and Behavior, 2011, 15, 1612-1622.	2.7	33
166	Women and Vulnerability to HAART Non-Adherence: A Literature Review of Treatment Adherence by Gender from 2000 to 2011. Current HIV/AIDS Reports, 2011, 8, 277-287.	3.1	125
167	Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infectious Diseases, 2011, 11, 86.	2.9	91
168	Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study. AIDS Research and Therapy, 2011, 8, 31.	1.7	1
169	Health system determinants of infant, child and maternal mortality: A cross-sectional study of UN member countries. Globalization and Health, 2011, 7, 42.	4.9	98
170	Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. Journal of the International AIDS Society, 2011, 14, 52-52.	3.0	55
171	Home is where the HAART is: an examination of factors affecting neighbourhood perceptions among people with HIV/AIDS on antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 245-251.	1.2	7
172	Cohort Profile: The Canadian Observational Cohort collaboration. International Journal of Epidemiology, 2011, 40, 25-32.	1.9	41
173	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal of Epidemiology, 2011, 174, 727-735.	3.4	9
174	Implications of the Henan Province Report on the Treatment as Prevention Debate. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e101.	2.1	7
175	Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine Among Treatment-Naive HIV-Infected Patients Initiating Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 38-46.	2.1	14
176	Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. Aids, 2011, 25, 851-855.	2.2	67
177	Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 980-987.	1.2	39
178	Dose-response Effect of Incarceration Events on Nonadherence to HIV Antiretroviral Therapy Among Injection Drug Users. Journal of Infectious Diseases, 2011, 203, 1215-1221.	4.0	147
179	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. Journal of Infectious Diseases, 2011, 204, 893-901.	4.0	33
180	Use of North America's First Medically Supervised Safer Injecting Facility Among HIV-Positive Injection Drug Users. AIDS Education and Prevention, 2011, 23, 412-422.	1.1	26

#	Article	IF	Citations
181	"Dynamic Range―of Inferred Phenotypic HIV Drug Resistance Values in Clinical Practice. PLoS ONE, 2011, 6, e17402.	2.5	3
182	Reply to †Evidence is still required for treatment as prevention for riskier routes of HIV transmission'. Aids, 2010, 24, 2892-2893.	2.2	1
183	Expanding access to HAART: a cost-effective approach for treating and preventing HIV. Aids, 2010, 24, 1929-1935.	2.2	63
184	A CD4+ Cell Count & lt;200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 451-459.	2.1	40
185	Expanded Highly Active Antiretroviral Therapy Coverage Among HIV-Positive Drug Users to Improve Individual and Public Health Outcomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S5-S9.	2.1	58
186	Drug and HIV-Related Risk Behaviors After Geographic Migration Among a Cohort of Injection Drug Users. AIDS and Behavior, 2010, 14, 854-861.	2.7	24
187	Insert Discourse: Rectal Douching Among Young HIV-Positive and HIV-Negative Men Who Have Sex with Men in Vancouver, Canada. Sexuality and Culture, 2010, 14, 327-343.	1.5	5
188	Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program. BMC Public Health, 2010, 10, 642.	2.9	5
189	Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. BMC Infectious Diseases, 2010, 10, 40.	2.9	14
190	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Research and Therapy, 2010, 7, 45.	1.7	73
191	Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction, 2010, 105, 907-913.	3.3	125
192	Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS ONE, 2010, 5, e10991.	2.5	42
193	Contraceptive Use and Method Preference among Women in Soweto, South Africa: The Influence of Expanding Access to HIV Care and Treatment Services. PLoS ONE, 2010, 5, e13868.	2.5	78
194	Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antiviral Therapy, 2010, 15, 789-796.	1.0	19
195	Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection. Clinical Infectious Diseases, 2010, 50, 98-105.	5.8	114
196	Epidemiology of Antiretroviral Multiclass Resistance. American Journal of Epidemiology, 2010, 172, 460-468.	3.4	15
197	HIV antiviral drug resistance: patient comprehension. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 816-826.	1.2	15
198	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases, 2010, 50, 1512-1520.	5.8	187

#	Article	IF	CITATIONS
199	Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 460-465.	2.1	135
200	Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet, The, 2010, 376, 532-539.	13.7	694
201	Reduction of HIV incidence in men who have sex with men. Lancet Infectious Diseases, The, 2010, 10, 655-656.	9.1	4
202	Factors behind HIV testing practices among Canadian Aboriginal peoples living off-reserve. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 324-331.	1.2	17
203	Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ: British Medical Journal, 2009, 338, b1649-b1649.	2.3	308
204	The Association Between Food Insecurity and Mortality Among HIV-Infected Individuals on HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 342-349.	2.1	189
205	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy–Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases, 2009, 49, 1582-1590.	5.8	55
206	Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Social Science and Medicine, 2009, 68, 1044-1049.	3.8	42
207	Antiretroviral Therapy is Associated with Increased Fertility Desire, but not Pregnancy or Live Birth, among HIV+ Women in an Early HIV Treatment Program in Rural Uganda. AIDS and Behavior, 2009, 13, 28-37.	2.7	129
208	Perceptions of HIV and Fertility Among Adolescents in Soweto, South Africa: Stigma and Social Barriers Continue to Hinder Progress. AIDS and Behavior, 2009, 13, 55-61.	2.7	11
209	The WHOMEN's Scale (Women's HAART Optimism Monitoring and EvaluatioN Scale v.1) and the Association with Fertility Intentions and Sexual Behaviours Among HIV-Positive Women in Uganda. AIDS and Behavior, 2009, 13, 72-81.	2.7	23
210	Editorial: Introduction to the Supplement on HIV, HAART, and Fertility in sub-Saharan Africa. AIDS and Behavior, 2009, 13, 1-4.	2.7	30
211	Food Insecurity is Associated with Incomplete HIV RNA Suppression Among Homeless and Marginally Housed HIV-infected Individuals in San Francisco. Journal of General Internal Medicine, 2009, 24, 14-20.	2.6	188
212	HIV/AIDS in Vancouver, British Columbia: a growing epidemic. Harm Reduction Journal, 2009, 6, 5.	3.2	36
213	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal of Medicine, 2009, 360, 1815-1826.	27.0	986
214	Epidemiology of treatment failure: a focus on recent trends. Current Opinion in HIV and AIDS, 2009, 4, 467-473.	3.8	12
215	Highly Active Antiretroviral Therapy and Increased Use of Contraceptives Among HIV-Positive Women During Expanding Access to Antiretroviral Therapy in Mbarara, Uganda. American Journal of Public Health, 2009, 99, 340-347.	2.7	56
216	The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 529-536.	2.1	255

#	Article	IF	Citations
217	Association Between HIV-1 RNA Level and CD4 Cell Count Among Untreated HIV-Infected Individuals. American Journal of Public Health, 2009, 99, S193-S196.	2.7	16
218	Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study. Antiviral Therapy, 2009, 14, 931-938.	1.0	20
219	Years of life lost to prison: racial and gender gradients in the United States of America. Harm Reduction Journal, 2008, 5, 4.	3.2	7
220	Factors associated with geographic migration among a cohort of injection drug users. Health and Place, 2008, 14, 536-543.	3.3	19
221	Predicting hospitalization among HIV-infected antiretroviral naÃ-ve patients starting HAART: Determining clinical markers and exploring social pathways. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 297-303.	1.2	10
222	Increased Resilience to the Development of Drug Resistance with Modern Boosted Protease Inhibitor–Based Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2008, 198, 51-58.	4.0	48
223	Nonadherence Increases the Risk of Hospitalization Among HIV-Infected Antiretroviral NaÃ-ve Patients Started on HAART. Journal of the International Association of Providers of AIDS Care, 2008, 7, 238-244.	1.2	44
224	CD4-Dependent Characteristics of Coreceptor Use and HIV Type 1 V3 Sequence in a Large Population of Therapy-Naive Individuals. AIDS Research and Human Retroviruses, 2008, 24, 219-228.	1.1	23
225	Expanded Access to Highly Active Antiretroviral Therapy: A Potentially Powerful Strategy to Curb the Growth of the HIV Epidemic. Journal of Infectious Diseases, 2008, 198, 59-67.	4.0	167
226	Validity of Self-Reported Adherence Among Injection Drug Users. Journal of the International Association of Providers of AIDS Care, 2008, 7, 157-159.	1.2	20
227	Highly Active Antiretroviral Therapy and Survival in HIV-Infected Injection Drug Users. JAMA - Journal of the American Medical Association, 2008, 300, 550.	7.4	198
228	â€Îlt's like the treasure': beliefs associated with semen among young HIVâ€positive and HIVâ€negative gay m Culture, Health and Sexuality, 2008, 10, 667-679.	nen. 1:8	24
229	Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. Aids, 2008, 22, 2371-2380.	2.2	147
230	Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply. Aids, 2008, 22, 548-549.	2.2	1
231	Impact of Neighborhood-Level Socioeconomic Status on HIV Disease Progression in a Universal Health Care Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 500-505.	2.1	108
232	The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 266-271.	2.1	52
233	Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. PLoS Pathogens, 2007, 3, e94.	4.7	153
234	Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 195, 1694-1704.	4.0	31

#	Article	IF	CITATIONS
235	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal of Epidemiology, 2007, 36, 294-301.	1.9	176
236	The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. Aids, 2007, 21, 1175-1183.	2.2	239
237	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids, 2007, 21, 1185-1197.	2.2	264
238	Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. Aids, 2007, 21, 1561-1568.	2.2	36
239	Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. Aids, 2007, 21, 685-692.	2.2	233
240	Migration and transmission of blood-borne infections among injection drug users: Understanding the epidemiologic bridge. Drug and Alcohol Dependence, 2007, 90, 107-119.	3.2	76
241	Rates of inappropriate antiretroviral prescription among injection drug users. Harm Reduction Journal, 2007, 4, 2.	3.2	7
242	Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index. AIDS Research and Therapy, 2007, 4, 1.	1.7	33
243	RATES OF HIV/AIDS CARE AND ANTIRETROVIRAL THERAPY RESPONSE AMONG ACTIVE INJECTION DRUG USERS. Addiction, 2007, 102, 1503-1505.	3.3	5
244	Nitrite inhalant use among young gay and bisexual men in Vancouver during a period of increasing HIV incidence. BMC Public Health, 2007, 7, 35.	2.9	39
245	The first ten years: achievements and challenges of the Brazilian program of universal access to HIV/AIDS comprehensive management and care, 1996-2006. Cadernos De Saude Publica, 2007, 23, S345-S359.	1.0	47
246	Sexual violence among two populations of men at high risk of HIV infection. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2006, 18, 681-689.	1.2	37
247	The direct costs of HIV/AIDS care. Lancet Infectious Diseases, The, 2006, 6, 171-177.	9.1	72
248	The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet, The, 2006, 368, 531-536.	13.7	460
249	Complementary and alternative medicine use in British Columbiaâ€"A survey of HIV positive people on antiretroviral therapy. Complementary Therapies in Clinical Practice, 2006, 12, 242-248.	1.7	47
250	Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug and Alcohol Dependence, 2006, 84, 188-194.	3.2	193
251	Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥ 200 cells/μI. Aids, 2006, 20, 1117-1123.	2.2	62
252	Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. Aids, 2006, 20, 445-450.	2.2	57

#	Article	IF	CITATIONS
253	Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. Aids, 2006, 20, 323-331.	2.2	43
254	Performance of Immunologic Responses in Predicting Viral Load Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 436-439.	2.1	73
255	Aboriginal status is a prognostic factor for mortality among antiretroviral na $ ilde{A}^-$ ve HIV-positive individuals first initiating HAART. AIDS Research and Therapy, 2006, 3, 14.	1.7	21
256	Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. Journal of Infection, 2006, 52, 233-236.	3.3	28
257	Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Drug and Alcohol Review, 2006, 25, 451-454.	2.1	11
258	Estimated Numbers of Men and Women Infected with HIV/AIDS in Tijuana, Mexico. Journal of Urban Health, 2006, 83, 299-307.	3.6	95
259	High Prevalence of Smoking Among Urban-Dwelling Canadian Men Who Have Sex with Men. Journal of Urban Health, 2006, 83, 1143-1150.	3.6	13
260	The potential impact of antiretroviral therapy on fertility in sub-Saharan Africa. Current HIV/AIDS Reports, 2006, 3, 187-194.	3.1	55
261	Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health and Place, 2006, 12, 79-85.	3.3	167
262	Illustrated Instructions for Self-Collection of Anorectal Swab Specimens and Their Adequacy for Cytological Examination. Sexually Transmitted Diseases, 2006, 33, 386-388.	1.7	24
263	The Impact of Sex Partners' HIV Status on HIV Seroconversion in a Prospective Cohort of Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 119-123.	2.1	6
264	Validity of Self-Reported Antiretroviral Therapy Use Among Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 530-531.	2.1	9
265	Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART. PLoS Medicine, 2006, 3, e356.	8.4	153
266	A Simple, Dynamic Measure of Antiretroviral Therapy Adherence Predicts Failure to Maintain HIVâ€1 Suppression. Journal of Infectious Diseases, 2006, 194, 1108-1114.	4.0	175
267	Self-Screening for Rectal Sexually Transmitted Infections: Human Papillomavirus. Clinical Infectious Diseases, 2006, 42, 308-309.	5.8	15
268	Immunologic Response to Antiretroviral Therapy in Hepatitis C Virus–Coinfected Adults in a Populationâ€Based HIV/AIDS Treatment Program. Journal of Infectious Diseases, 2006, 193, 259-268.	4.0	45
269	Randomized clinical evaluation of self-screening for anal cancer precursors in men who have sex with men. CytoJournal, 2006, 3, 4.	1.7	31
270	Factors Associated With Buying and Selling Syringes Among Injection Drug Users in a Setting of One of North America's Largest Syringe Exchange Programs. Substance Use and Misuse, 2006, 41, 883-899.	1.4	5

#	Article	IF	Citations
271	Requiring Help Injecting Independently Predicts Incident HIV Infection Among Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 83-88.	2.1	76
272	Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 288-293.	2.1	134
273	Similar Sexual Behaviors With Casual Partners Among Gay Men With and Without a Regular Partner. Sexually Transmitted Diseases, 2005, 32, 203-205.	1.7	2
274	Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal, 2005, 2, 24.	3.2	87
275	HIV prevalence among aboriginal British Columbians. Harm Reduction Journal, 2005, 2, 26.	3.2	16
276	Sociodemographic Disparities in Access to Addiction Treatment Among a Cohort of Vancouver Injection Drug Users. Substance Use and Misuse, 2005, 40, 1153-1167.	1.4	40
277	Treatment Interruption of Highly Active Antiretroviral Therapy in Patients with Nadir CD4 Cell Counts >200 Cells/mm3. Journal of Infectious Diseases, 2005, 192, 1787-1793.	4.0	30
278	Molecular and Clinical Epidemiology of CXCR4â€Using HIVâ€1 in a Large Population of Antiretroviralâ€Naive Individuals. Journal of Infectious Diseases, 2005, 192, 466-474.	4.0	260
279	Global IDEA. Cmaj, 2005, 172, 1537-1538.	2.0	1
280	Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. Cmaj, 2005, 173, 160-164.	2.0	20
281	Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. Cmaj, 2005, 172, 479-483.	2.0	22
282	Back to work: Correlates of employment among persons receiving highly active antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2005, 17, 740-746.	1.2	23
283	Nonadherence to Antiretroviral Therapy Among a Community With Endemic Rates of Injection Drug Use. Journal of the International Association of Providers of AIDS Care, 2005, 4, 66-72.	1.2	21
284	Structured Treatment Interruptions: A Risky Business. Clinical Infectious Diseases, 2005, 40, 601-603.	5.8	13
285	Predictors of HIV Drugâ€Resistance Mutations in a Large Antiretroviralâ€Naive Cohort Initiating Triple Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 191, 339-347.	4.0	386
286	Sustained Increase in HIV-1 Incidence Since 2000 Among Men Who Have Sex With Men in British Columbia, Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 242-244.	2.1	16
287	When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infectious Diseases, The, 2005, 5, 407-414.	9.1	51
288	Factors associated with sex-trade involvement among female injection drug users in a Canadian setting. Addiction Research and Theory, 2005, 13, 193-199.	1.9	16

#	Article	IF	CITATIONS
289	Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids in Health and Disease, 2005, 4, 4.	3.0	27
290	BCL-2 Expression May Adversely Affect Outcome in HIV-Associated Systemic Diffuse Large B Cell Lymphoma Blood, 2005, 106, 4674-4674.	1.4	1
291	Association of the CCR5î"32 Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen. Antiviral Therapy, 2005, 10, 849-853.	1.0	7
292	Antiretroviral Resistance among HIVâ€Infected Persons Who Have Died in British Columbia, in the Era of Modern Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 285-292.	4.0	36
293	Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids, 2004, 18, F1-F9.	2.2	80
294	Inability to Access Addiction Treatment and Risk of HIV Infection Among Injection Drug Users. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 750-754.	2.1	31
295	Unprotected Anal Intercourse Associated With Recreational Drug Use Among Young Men Who Have Sex With Men Depends on Partner Type and Intercourse Role. Sexually Transmitted Diseases, 2004, 31, 492-498.	1.7	82
296	Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users. International Journal of Epidemiology, 2004, 34, 152-158.	1.9	22
297	Trends in antenatal human immunodeficiency virus prevalence in Western Kenya and Eastern Uganda: evidence of differences in health policies?. International Journal of Epidemiology, 2004, 33, 542-548.	1.9	8
298	Nucleoside-Related Mitochondrial Toxicity among HIV-Infected Patients Receiving Antiretroviral Therapy: Insights from the Evaluation of Venous Lactic Acid and Peripheral Blood Mitochondrial DNA. Clinical Infectious Diseases, 2004, 38, S73-S79.	5.8	40
299	Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health. International Journal of Drug Policy, 2004, 15, 133-138.	3.3	11
300	The potential health and economic impact of implementing a medically prescribed heroin program among Canadian injection drug users. International Journal of Drug Policy, 2004, 15, 259-263.	3.3	10
301	Sexual Risk Profile of Young Men in Vancouver, British Columbia, Who Have Sex with Men and Inject Drugs. AIDS and Behavior, 2004, 8, 17-23.	2.7	33
302	The Cost of Inaction on HIV Transmission among Injection Drug Users and the Potential for Effective Interventions. Journal of Urban Health, 2004, 81, 655-660.	3.6	16
303	Impairments, activity limitations and participation restrictions: prevalence and associations among persons living with HIV/AIDS in British Columbia. Health and Quality of Life Outcomes, 2004, 2, 46.	2.4	133
304	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	13.7	303
305	Is "3 by 5―enough? Recalculating the global need for antiretroviral treatment. Lancet, The, 2004, 364, 1034-1035.	13.7	4
306	Displacement of Canada's largest public illicit drug market in response to a police crackdown. Cmaj, 2004, 170, 1551-1556.	2.0	158

#	Article	IF	CITATIONS
307	Intensive care unit survivors have fewer hospital readmissions and readmission days than other hospitalized patients in British Columbia. Critical Care Medicine, 2004, 32, 391-398.	0.9	21
308	Gender Differences in HIV-1 RNA Rebound Attributed to Incomplete Antiretroviral Adherence Among HIV-Infected Patients in a Population-Based Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1470-1476.	2.1	41
309	The Impact of Adherence on CD4 Cell Count Responses Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 261-268.	2.1	133
310	Psychosocial Determinants of Adherence to Highly Active Antiretroviral Therapy among Injection Drug Users in Vancouver. Antiviral Therapy, 2004, 9, 407-414.	1.0	56
311	Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes. Antiviral Therapy, 2004, 9, 713-719.	1.0	104
312	Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users. Antiviral Therapy, 2004, 9, 229-235.	1.0	56
313	Fast Track to Atlantis. Journal of Urban Health, 2003, 80, 361-362.	3.6	0
314	Alcohol Use and Incarceration Adversely Affect HIV-1 RNA Suppression Among Injection Drug Users Starting Antiretroviral Therapy. Journal of Urban Health, 2003, 80, 667-675.	3.6	60
315	Sexual violence among a cohort of injection drug users. Social Science and Medicine, 2003, 57, 561-569.	3.8	105
316	Non-consensual sex experienced by men who have sex with men: prevalence and association with mental health. Patient Education and Counseling, 2003, 49, 67-74.	2.2	85
317	Higher Baseline Levels of Plasma Human Immunodeficiency Virus Type 1 RNA Are Associated with Increased Mortality after Initiation of Tripleâ€Drug Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 188, 1421-1425.	4.0	45
318	Prevalence and Correlates of Untreated Human Immunodeficiency Virus Type 1 Infection among Persons Who Have Died in the Era of Modern Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 188, 1164-1170.	4.0	100
319	Rates of Disease Progression among Human Immunodeficiency Virus–Infected Persons Initiating Multipleâ€Drug Rescue Therapy. Journal of Infectious Diseases, 2003, 188, 137-141.	4.0	13
320	Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease. Journal of Infectious Diseases, 2003, 188, 541-548.	4.0	52
321	Mitochondrial:Nuclear DNA Ratios in Peripheral Blood Cells from Human Immunodeficiency Virus (HIV)–Infected Patients Who Received Selected HIV Antiretroviral Drug Regimens. Journal of Infectious Diseases, 2003, 187, 1972-1976.	4.0	81
322	Mitochondrial Toxicity in the Era of HAART: Evaluating Venous Lactate and Peripheral Blood Mitochondrial DNA in HIV-Infected Patients Taking Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, S85-S90.	2.1	61
323	Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 522-526.	2.1	113
324	CD4 Cell Count Response to Nonnucleoside Reverse Transcriptase Inhibitor- or Protease Inhibitor-Based Highly Active Antiretroviral Therapy in an Observational Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 347-348.	2.1	7

#	Article	IF	Citations
325	Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995–2000. Aids, 2003, 17, 2071-2075.	2.2	6
326	Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. Aids, 2003, 17, 2419-2427.	2.2	66
327	Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. Aids, 2003, 17, 201-208.	2.2	85
328	Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?. Aids, 2003, 17, 711-720.	2.2	107
329	Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. Aids, 2003, 17, 2629-2634.	2.2	13
330	Health and Socioeconomic Status Differences Among Antibody Hepatitis C Positive and Negative Transfusion Recipients, 1986–1990. Canadian Journal of Public Health, 2003, 94, 130-134.	2.3	1
331	Determinants of HIV serconversion in an era of increasing HIV infection among young gay and bisexual men. Aids, 2003, 17, 774-777.	2.2	27
332	Prevalence and clinical implications of insertions in the HIV-1 p6 ^{Gag} N-terminal region in drug-naive individuals initiating antiretroviral therapy. Antiviral Therapy, 2003, 8, 91-96.	1.0	16
333	Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill. Antiviral Therapy, 2003, 8, 471-478.	1.0	47
334	Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings. Antiviral Therapy, 2003, 8, 379-384.	1.0	16
335	Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme. Antiviral Therapy, 2003, 8, 569-576.	1.0	19
336	Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. Aids, 2002, 16, 1051-1058.	2.2	371
337	Azithromycin Prophylaxis for Mycobacterium avium Complex during the Era of Highly Active Antiretroviral Therapy: Evaluation of a Provincial Program. Clinical Infectious Diseases, 2002, 34, 371-378.	5.8	23
338	No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy. Aids, 2002, 16, 1929-1933.	2.2	37
339	To stop or not to stop: That is the question, but what is the answer?. Aids, 2002, 16, 787-789.	2.2	11
340	Prescribing practices in a population-based HIV postexposure prophylaxis program. Aids, 2002, 16, 1067-1070.	2.2	7
341	Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. Aids, 2002, 16, 2065-2072.	2.2	117
342	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.	13.7	1,415

#	Article	IF	Citations
343	Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet, The, 2002, 360, 1710-1711.	13.7	39
344	Needle exchange and difficulty with needle access during an ongoing HIV epidemic. International Journal of Drug Policy, 2002, 13, 95-102.	3.3	74
345	Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. Aids, 2002, 16, 941-943.	2.2	127
346	Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. Aids, 2002, 16, 1693-1695.	2.2	15
347	Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. Aids, 2001, 15, 61-69.	2.2	75
348	CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. Aids, 2001, 15, 2259-2266.	2.2	29
349	Socio-Demographic Profile and Hiv and Hepatitis C Prevalence Among Persons Who Died of a Drug Overdose. Addiction Research and Theory, 2001, 9, 459-470.	1.9	8
350	Longitudinal Patterns of Sexual Behavior and Condom Use in a Cohort of HIV-Negative Gay and Bisexual Men in Vancouver, British Columbia, Canada, 1995–2000. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 187-193.	2.1	10
351	"Being dealt with as a whole person.―Care seeking and adherence: the benefits of culturally competent care. Social Science and Medicine, 2001, 52, 1643-1659.	3.8	97
352	Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. Aids, 2001, 15, 231-239.	2.2	216
353	Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. Aids, 2001, 15, 423-424.	2.2	48
354	Mary-Jane and her patients: sociodemographic and clinical characteristics of HIV-positive individuals using medical marijuana and antiretroviral agents. Aids, 2001, 15, 532-533.	2.2	28
355	Increasing incidence of HIV infections among young gay and biseuxal men in Vancouver. Aids, 2001, 15, 1321-1322.	2.2	67
356	Another reality check: the direct costs of providing post-exposure prophylaxis in a population-based programme. Aids, 2001, 15, 2345-2347.	2.2	4
357	A compromise strategy for patients with multiple drug failure. Aids, 2001, 15, 2470.	2.2	8
358	Comparison of sexual behaviors, unprotected sex, and substance use between two independent cohorts of gay and bisexual men. Aids, 2000, 14, 303-311.	2.2	24
359	Antiretroviral medication use among injection drug users: two potential futures. Aids, 2000, 14, 1229-1235.	2.2	50
360	Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. Aids, 2000, 14, 1955-1960.	2.2	61

#	Article	IF	CITATIONS
361	Determinants of geographic mobility among participants in a population-based HIV/AIDS drug treatment program. Health and Place, 2000, 6, 33-40.	3.3	25
362	The end of the line: has rapid transit contributed to the spatial diffusion of HIV in one of Canada's largest metropolitan areas?. Social Science and Medicine, 2000, 51, 741-748.	3.8	21
363	Title is missing!. AIDS and Behavior, 2000, 4, 271-278.	2.7	18
364	The impact of zidovudine on dementia-free survival in a population of HIV-positive men and women on antiretroviral therapy. International Journal of STD and AIDS, 2000, 11, 52-56.	1.1	4
365	The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS. Pharmacoeconomics, 2000, 18, 393-404.	3.3	27
366	Morbidity and Mortality Related to Human Immunodeficiency Virus in Canadian Men and Women, 1987–94. Canadian Journal of Public Health, 1999, 90, 127-132.	2.3	4
367	HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men. International Journal of STD and AIDS, 1999, 10, 582-587.	1.1	17
368	"A Lot of Things I Hide― Understanding Disclosure in the Care of HIV-Positive Bisexual Men. Journal of the Gay and Lesbian Medical Association, 1999, 3, 119-126.	0.6	3
369	Social inequalities in male mortality amenable to medical intervention in British Columbia. Social Science and Medicine, 1999, 48, 1751-1758.	3 . 8	42
370	Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. Aids, 1999, 13, 1863-1871.	2.2	109
371	Antiretroviral Effect of Two Different Dose Regimens of Ritonavir and Saquinavir on HIV-Infected Adults in a Population-Based Setting. Antiviral Therapy, 1999, 4, 151-156.	1.0	0
372	"They Don't See Our Feelings.―The Health Care Experiences of HIV-Positive Transgendered Persons. Journal of the Gay and Lesbian Medical Association, 1998, 2, 103-111.	0.6	10
373	Modelling the Potential Economic Impact of Viral Load???Driven Triple Drug Combination Antiretroviral Therapy. Pharmacoeconomics, 1998, 13, 697-705.	3.3	25
374	Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV-Positive Adult Men and Women. Pharmacoeconomics, 1998, 13, 327-336.	3.3	14
375	Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 1998, 279, 450.	7.4	754
376	Antiviral effect of double and triple drug combinations amongst HIV-infected adults. Aids, 1998, 12, 279-284.	2.2	79
377	One world, one hope. Aids, 1998, 12, 2203-2209.	2,2	27
378	HIV/AIDS care giving physicians: their experience and practice patterns. International Journal of STD and AIDS, 1997, 8, 570-575.	1.1	3

#	Article	IF	CITATIONS
379	Physician concurrence with primary care guidelines for persons with HIV disease. International Journal of STD and AIDS, 1997, 8, 609-613.	1.1	7
380	Emerging international consensus for use of antiretroviral therapy. Lancet, The, 1997, 349, 1042.	13.7	14
381	Heterogeneity of care for HIV-infected individuals decreases with the physician knowledge. International Journal of STD and AIDS, 1996, 7, 435-438.	1.1	7
382	Asthma Mortality in Canada, 1946 to 1990. Canadian Respiratory Journal, 1995, 2, 61-66.	1.6	10
383	Indigenous mortality: Placing Australian aboriginal mortality within a broader context. Social Science and Medicine, 1992, 35, 335-346.	3.8	38